secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008525
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma Q1 2022 revenue $5.9M; cash $192.1M; STRO-002 data expected H2 2022
--------------------------------------------------------------------------------

- Revenue $5.9M vs $14.7M YoY; operating expenses $45.0M vs $33.7M; net loss not stated directly.
- Cash, cash equivalents and marketable securities $192.1M as of Mar 31, 2022; runway into H2 2023.
- Phase 1 dose-expansion data for STRO-002 (ovarian cancer) expected H2 2022; regulatory meetings planned mid-2022.
- First patient dosed in STRO-002 + bevacizumab combo trial; endometrial cohort enrolling.
- Tasly amended STRO-002 license: $25M upfront, up to $350M in milestones; Tasly to fund Greater China development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022008525/0000950170-22-008525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022008525/stro-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer